• Share

Sign Up. Stay Informed.

Receive updates from the Dymista Team.

ALL fields are required to complete your enrollment.

Please fill out the Required fields

Please agree to the terms and conditions

I confirm, I have read the Viatris Privacy Notice at www.viatris.com/en/privacy-policy and agree that Viatris Inc., its affiliates and subsidiaries (“Viatris”) may use my personal data to provide me with scientific information and information on pharmaceutical products as well as events, webinars or surveys. I understand and acknowledge that all information processed by Viatris is handled in accordance with local privacy laws and may be captured and processed in countries outside of the jurisdiction in which it was collected. In order to improve its emails, websites and information services, Viatris may track whether I received an email, opened it, clicked on any links, viewed or downloaded any documents within it. I understand that my consent is voluntary and I can withdraw my consent at any time. The withdrawal of consent will not affect the lawfulness of processing based on consent before its withdrawal. I acknowledge that I am not obliged to provide my personal information. However, if I do not provide the information, I may not, for example, be able to participate fully in activities managed by Viatris.

More IMPORTANT SAFETY INFORMATION (the following information applies to both DYMISTA and its Authorized Generic)

  • Somnolence: Avoid engaging in hazardous occupations requiring complete mental alertness such as driving or operating machinery when taking DYMISTA.
  • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with DYMISTA because further decreased alertness and impairment of CNS performance may occur.
  • Epistaxis, nasal ulcerations, nasal septal perforation, impaired wound healing, Candida albicans infection: Monitor patients periodically for signs of adverse effects on the nasal mucosa. Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma.
  • Glaucoma or posterior subcapsular cataracts: Monitor patients closely with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.
  • Potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. More serious or even fatal course of chickenpox or measles in susceptible patients. Use caution in patients with the above because of the potential for worsening of these infections.
  • Hypercorticism and adrenal suppression with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue DYMISTA slowly.
  • Potential reduction in growth velocity in children. Monitor growth routinely in pediatric patients receiving DYMISTA.
  • Potent inhibitors of cytochrome P450 (CYP) 3A4: May increase blood levels of fluticasone propionate.
  • Ritonavir: Coadministration is not recommended.
  • Other potent CYP3A4 inhibitors, such as ketoconazole: use caution with coadministration.
  • The most common adverse reaction (≥2% incidence) are dysgeusia, epistaxis, and headache.

INDICATIONS (the following information applies to both DYMISTA and its Authorized Generic)

DYMISTA is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older.

For additional information please contact us at 800-395-3376.

Click here for Full Prescribing Information for DYMISTA
Click here for Full Prescribing Information for the Authorized Generic for DYMISTA

You are about to enter mylan.com to view copyright and legal information.

You are now leaving dymista.com/hcp

You are about to enter mylan.com to view privacy statement.

You are now leaving dymista.com/hcp

You are about to enter dymista.com, the patient site, to find out more about the Dymista Savings Card.

Prescribing Information

Please select from the following:

You are now leaving dymista.com/hcp

You are about to enter dymista.com, the patient site.